MedTrace Logo

Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia

NCT07537738 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 210

Last updated 2026-04-17

No results posted yet for this study

Summary

The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement. The main question it aims to answer is:

• Could be leukemia stem cell used for relapse prediction in acute myeloid leukemia patients with MLL-rearrangement? Leukemia stem cell will be detected at the same time for participants who detected minimal residual disease using bone marrow as part of their regular medical care to answer the question.

Conditions

  • Acute Myeloid Leukemia (AML)
  • MLL Rearrangement

Interventions

DIAGNOSTIC_TEST

Detection of leukemia stem cell using multiparameter flow cytometry

For AML patients with MLL rearrangement enrolled, leukemia stem cell will be detcted at diagnosis and during follow-up. A traditional Minimal residual disease was deteced as normal medical care, simultaneously, leukemia stem cell will be detcted using the sample bone marrow sample.

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Eligibility

Min Age
6 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2026-04-07
Completion
2026-04-07

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07537738 on ClinicalTrials.gov